Yonhap Infomax NewsCelltrion's biosimilar Truxima captures 35.8% US prescription market share as of February 2026, becoming the top rituximab drug six years after market entry, with North American sales exceeding 300 billion won and 40% year-over-year growth demonstrating strong competitive positioning in the world's largest pharmaceutical market.
#YonhapInfomax #Celltrion #Truxima #US Market Share #Rituximab #Biosimilar #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=114173
#YonhapInfomax #Celltrion #Truxima #US Market Share #Rituximab #Biosimilar #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=114173
Celltrion's Truxima Achieves No. 1 Market Share in US
Celltrion's biosimilar Truxima captures 35.8% US prescription market share as of February 2026, becoming the top rituximab drug six years after market entry, with North American sales exceeding 300 billion won and 40% year-over-year growth demonstrating strong competitive positioning in the world's largest pharmaceutical market.